Humulin R U-100

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Humulin R U-100 is a short-acting regular human insulin (100 IU/ml). It is prescribed for type 1 and type 2 diabetes mellitus, usually alongside a longer-acting insulin or other antidiabetic medicines, and works like the body’s own insulin to help glucose enter the cells and to reduce glucose production in the liver.

Active ingredient
Regular human insulin (rDNA origin)
Strength
U-100 (100 IU/ml)
Dosage form
Solution for injection
Therapeutic class
Short-acting insulin
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with regular human insulin and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Management of type 1 and type 2 diabetes mellitus
  • Usually combined with a long-acting insulin or other antidiabetic medicines
  • Described as starting to act within about 30 minutes of injection
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Given by subcutaneous injection, typically 20–30 minutes before a meal, per prescribing information
  • Dose and duration are set by the prescriber; injection technique is taught by a healthcare professional
  • Regular meals and regular blood glucose monitoring are advised, with results shared with the prescriber

Described Side Effects

Commonly described side effects include:

  • Low blood glucose (hypoglycaemia) — cold sweat, shakiness, hunger, fast heart rate, nervousness
  • Weight gain
  • Injection-site reactions (pain, swelling, redness)
  • Headache

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Should not be used when blood sugar is already low
  • Kidney, liver, or heart problems should be disclosed to the prescriber
  • Pregnancy or breastfeeding should be discussed before use
  • Blood glucose should be monitored regularly and meals taken consistently

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling, it is a short-acting regular human insulin used for type 1 and type 2 diabetes mellitus, often with a longer-acting insulin. SDO Pharma has not independently verified these claims.

By subcutaneous injection, generally 20–30 minutes before a meal, using the technique and dose taught by a healthcare professional.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services